Lipid composition heatmap for Study ST001237

Select 2 experimental conditions (at least one from A and at least one from B) to compare lipid profiles.
Group ACombined factors (this analysis)Group B
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE
Select a lipid RefMet sub class:    

Lipid sub classes in this studyNumber in study
Acyl carnitines24
Cer2
DAG3
LPC10
LPE7
O-LPC3
O-PC4
O-PE8
O-PS1
PC5
PE7
SM7
Unsaturated FA1
  logo